6mfj: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "6mfj" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of the ADCC potent antibody DH677.3 Fab elicited in the RV305 vaccine trial.== | |||
<StructureSection load='6mfj' size='340' side='right'caption='[[6mfj]], [[Resolution|resolution]] 2.62Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6mfj]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MFJ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MFJ FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
[[Category: | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6mfj FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mfj OCA], [http://pdbe.org/6mfj PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6mfj RCSB], [http://www.ebi.ac.uk/pdbsum/6mfj PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6mfj ProSAT]</span></td></tr> | ||
</table> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Human]] | |||
[[Category: Large Structures]] | |||
[[Category: Pazgier, M]] | [[Category: Pazgier, M]] | ||
[[Category: Tolbert, W | [[Category: Tolbert, W D]] | ||
[[Category: Young, B]] | [[Category: Young, B]] | ||
[[Category: Adcc]] | |||
[[Category: Anti-hiv-1 env antibody dh677 3]] | |||
[[Category: Cd4i antibody]] | |||
[[Category: Hiv-1 env]] | |||
[[Category: Immune system]] | |||
[[Category: Rv305 vaccine trial]] | |||
Revision as of 10:55, 18 December 2019
Crystal structure of the ADCC potent antibody DH677.3 Fab elicited in the RV305 vaccine trial.
| ||||||||||||
